Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 December;61(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 December;61(4):414-28

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REVIEW  NEWS AND VIEWS ON CLINICAL NEUROIMAGING


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 December;61(4):414-28

DOI: 10.23736/S1824-4785.17.03019-9

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

News and views on in-vivo imaging of neurotransmission using PET and MRI

Christin Y. SANDER 1, 2 , Swen HESSE 3, 4

1 Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA; 2 Harvard Medical School, Boston, MA, USA; 3 Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; 4 Integrated Treatment and Research Center (IFB) Adiposity Diseases, Leipzig University Medical Center, Leipzig, Germany


PDF  


Molecular neuroimaging with PET is an integrated tool in psychiatry research and drug-development for as long as this modality has been available, in particular for studying neurotransmission and endogenous neurotransmitter release. Pharmacologic, behavioral and other types of challenges are currently applied to induce changes in neurochemical levels that can be inferred through their effects on changes in receptor binding and related outcome measures. Based on the availability of tracers that are sensitive for measuring neurotransmitter release these experiments have focused on the brain’s dopamine system, while recent developments have extended those studies to other targets such as the serotonin or choline system. With the introduction of hybrid, truly simultaneous PET/MRI systems, in-vivo imaging of the dynamics of neuroreceptor signal transmission in the brain using PET and functional MRI (fMRI) has become possible. fMRI has the ability to provide information about the effects of receptor function that are complementary to the PET measurement. Dynamic acquisition of both PET and fMRI signals enables not only an in-vivo real-time assessment of neurotransmitter or drug binding to receptors but also dynamic receptor adaptations and receptor-specific neurotransmission. While fMRI temporal resolution is comparatively fast in relation to PET, the timescale of observable biological processes is highly dependent on the kinetics of radiotracers and study design. Overall, the combination of the specificity of PET radiotracers to neuroreceptors, fMRI signal as a functional readout and integrated study design promises to expand our understanding of the location, propagation and connections of brain activity in health and disease.


KEY WORDS: Positron-emission tomography - Dopamine - Synaptic transmission

inizio pagina

Publication History

Issue published online: September 20, 2017
Article first published online: July 27, 2017
Manuscript accepted: July 25, 2017
Manuscript received: July 18, 2017

Per citare questo articolo

Sander CY, Hesse S. News and views on in-vivo imaging of neurotransmission using PET and MRI. Q J Nucl Med Mol Imaging 2017;61:414-28. DOI: 10.23736/S1824-4785.17.03019-9

Corresponding author e-mail

csander@mgh.harvard.edu